Free Trial

Embecta (EMBC) Competitors

Embecta logo
$14.10 -0.31 (-2.15%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$15.21 +1.11 (+7.87%)
As of 02/21/2025 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EMBC vs. WRBY, LIVN, ENOV, NVCR, TMDX, LMAT, TNDM, SLNO, CNMD, and CDRE

Should you be buying Embecta stock or one of its competitors? The main competitors of Embecta include Warby Parker (WRBY), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), TransMedics Group (TMDX), LeMaitre Vascular (LMAT), Tandem Diabetes Care (TNDM), Soleno Therapeutics (SLNO), CONMED (CNMD), and Cadre (CDRE). These companies are all part of the "medical equipment" industry.

Embecta vs.

Warby Parker (NYSE:WRBY) and Embecta (NASDAQ:EMBC) are both consumer staples companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Embecta has higher revenue and earnings than Warby Parker. Warby Parker is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Warby Parker$742.53M3.29-$63.20M-$0.27-89.00
Embecta$1.12B0.73$78.30M$1.0014.10

Warby Parker has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500. Comparatively, Embecta has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

In the previous week, Warby Parker had 3 more articles in the media than Embecta. MarketBeat recorded 9 mentions for Warby Parker and 6 mentions for Embecta. Warby Parker's average media sentiment score of 0.54 beat Embecta's score of 0.34 indicating that Warby Parker is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Warby Parker
3 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Embecta
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Warby Parker presently has a consensus target price of $21.92, indicating a potential downside of 8.76%. Embecta has a consensus target price of $23.00, indicating a potential upside of 63.12%. Given Embecta's higher probable upside, analysts plainly believe Embecta is more favorable than Warby Parker.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Warby Parker
1 Sell rating(s)
5 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.50
Embecta
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Embecta has a net margin of 5.25% compared to Warby Parker's net margin of -4.39%. Warby Parker's return on equity of -8.26% beat Embecta's return on equity.

Company Net Margins Return on Equity Return on Assets
Warby Parker-4.39% -8.26% -4.37%
Embecta 5.25%-19.22%11.92%

Warby Parker received 39 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 42.11% of users gave Warby Parker an outperform vote while only 6.25% of users gave Embecta an outperform vote.

CompanyUnderperformOutperform
Warby ParkerOutperform Votes
40
42.11%
Underperform Votes
55
57.89%
EmbectaOutperform Votes
1
6.25%
Underperform Votes
15
93.75%

93.2% of Warby Parker shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 26.5% of Warby Parker shares are held by insiders. Comparatively, 0.4% of Embecta shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Warby Parker beats Embecta on 9 of the 17 factors compared between the two stocks.

Get Embecta News Delivered to You Automatically

Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EMBC vs. The Competition

MetricEmbectaSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$819.69M$4.71B$5.85B$9.15B
Dividend Yield3.88%39.90%4.76%3.85%
P/E Ratio14.1014.9116.5114.19
Price / Sales0.7452.72450.0276.60
Price / Cash4.3251.1038.0134.95
Price / Book-1.076.577.644.63
Net Income$78.30M$90.13M$3.18B$245.69M
7 Day Performance-5.05%-2.20%-1.95%-2.68%
1 Month Performance-24.76%-2.17%-0.23%-2.16%
1 Year Performance-4.41%15.26%16.69%12.90%

Embecta Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EMBC
Embecta
4.807 of 5 stars
$14.10
-2.2%
$23.00
+63.1%
-5.7%$819.69M$1.11B14.102,100Short Interest ↓
High Trading Volume
WRBY
Warby Parker
2.5521 of 5 stars
$25.70
-2.7%
$21.77
-15.3%
+71.6%$2.61B$669.77M-95.193,491Upcoming Earnings
Analyst Forecast
LIVN
LivaNova
3.5845 of 5 stars
$47.68
+0.1%
$69.17
+45.1%
-16.5%$2.59B$1.15B113.522,900Upcoming Earnings
ENOV
Enovis
3.4615 of 5 stars
$43.89
+0.4%
$64.83
+47.7%
-29.1%$2.50B$1.71B-20.046,550Short Interest ↓
Positive News
NVCR
NovoCure
3.4827 of 5 stars
$22.48
+3.5%
$32.67
+45.3%
+41.4%$2.43B$509.34M-16.061,453Upcoming Earnings
News Coverage
TMDX
TransMedics Group
3.6199 of 5 stars
$72.18
+1.3%
$122.70
+70.0%
-17.3%$2.42B$241.62M76.79210News Coverage
Gap Up
LMAT
LeMaitre Vascular
2.0498 of 5 stars
$98.65
+1.7%
$94.63
-4.1%
+59.9%$2.22B$193.48M53.91490Positive News
TNDM
Tandem Diabetes Care
4.0971 of 5 stars
$33.47
+2.6%
$53.81
+60.8%
+37.5%$2.20B$747.72M-17.342,400Positive News
SLNO
Soleno Therapeutics
4.5423 of 5 stars
$49.17
-4.2%
$71.20
+44.8%
-5.1%$2.12BN/A-14.8130News Coverage
Positive News
CNMD
CONMED
4.7777 of 5 stars
$63.05
-2.1%
$77.20
+22.4%
-25.1%$1.95B$1.31B14.874,000
CDRE
Cadre
2.9308 of 5 stars
$35.14
-1.6%
$39.67
+12.9%
-5.2%$1.43B$482.53M42.342,435

Related Companies and Tools


This page (NASDAQ:EMBC) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners